Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luconosatuzumab plus toripalimab in advanced gastric or gastroesophageal junction cancer after failure of first-line immunotherapy
ChiCTR2600122518Phase 2Not yet recruiting
- Sponsor
- Huadong Hospital, Fudan University
- Start
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of luconosatuzumab and toripalimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Huadong Hospital, Fudan University. Primary endpoint: Objective response rate (ORR). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
luconosatuzumabtoripalimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600122518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122518.